☆ 4.6 Meeting Abstract

Feasibility of outpatient dinutuximab (D) and irinotecan (I) for second-line treatment of relapsed or refractory small cell lung cancer (RR SCLC): Part 1 of an open-label, randomized, phase 2/3 study

JOURNAL OF THORACIC ONCOLOGY (2018)

Get Full Text
Add to Collection

Journal

JOURNAL OF THORACIC ONCOLOGY
Volume 13, Issue 4, Pages S48-S49

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S1556-0864(18)30363-0

Keywords

-

Categories

Oncology Respiratory System

Funding

  1. United Therapeutics Corporation

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.